1. Home
  2. BLIN vs LNAI Comparison

BLIN vs LNAI Comparison

Compare BLIN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

HOLD

Current Price

$1.15

Market Cap

12.9M

Sector

Technology

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$3.26

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLIN
LNAI
Founded
2000
N/A
Country
United States
United States
Employees
N/A
29
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
11.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BLIN
LNAI
Price
$1.15
$3.26
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.62
N/A
AVG Volume (30 Days)
70.7K
674.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,568,000.00
N/A
Revenue This Year
$22.67
N/A
Revenue Next Year
$21.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$0.15
52 Week High
$1.74
$5.02

Technical Indicators

Market Signals
Indicator
BLIN
LNAI
Relative Strength Index (RSI) 61.58 57.09
Support Level $0.77 $0.57
Resistance Level $1.30 $3.38
Average True Range (ATR) 0.10 0.59
MACD -0.00 -0.02
Stochastic Oscillator 87.36 33.54

Price Performance

Historical Comparison
BLIN
LNAI

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: